LAURA Updated OS
LAURA: Updated Overall Survival for Phase III Trial of Osimertinib vs Placebo After Definitive Chemoradiotherapy for Unresectable Stage III EGFR-Mutated NSCLC

Released: April 09, 2025

Expiration: October 08, 2025

Activity

Progress
1
Course Completed
Activity Information

Released: April 09, 2025

Expiration: October 08, 2025